Breaking News

When cancer cells are like a vampire

October 13, 2023
Illustration of mitochondria, powerhouse of the cell.
Adobe

STAT+ | Like a vampire, some cancer cells can suck the energy source from immune cells

The discovery that some tumors steal mitochondria from T-cells via nanotubes could help explain why immunotherapy sometimes fails.

By Angus Chen


STAT+ | Dana-Farber CEO on Mass General split: Boston needed a dedicated cancer hospital

Dana-Farber's split with Mass General was spurred by a disagreement over the need for a dedicated cancer hospital, its CEO said Tuesday

By Tara Bannow


STAT+ | Amgen reports first clinical data on new targeted cancer therapy

The company's preliminary results showed five partial responses from 31 evaluable patients who received the treatment.

By Adam Feuerstein



Jason Buenrostro in his Harvard lab.
Courtesy John D. and Catherine T. MacArthur Foundation

He was named a MacArthur 'genius' fellow for research on gene regulation, but still has imposter syndrome

Even now, the Harvard researcher sometimes has imposter syndrome: "I'll walk into a room and be like, do I really deserve to be here?"

By Anika Nayak


STAT+ | EU orders Illumina to divest cancer diagnostics firm Grail

The move Thursday was the latest regulatory action against the 2021 acquisition, which is also facing challenges from the U.S.

By Andrew Joseph


STAT+ | Sana to lay off nearly a third of staff, de-prioritize a key program

Sana Biotechnology, a startup that just a couple years ago raised over $1 billion, will lay off employees and delay a key program.

By Jason Mast


More around STAT
Check out more exclusive coverage with a STAT+ subscription
Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

Enjoying Cancer Briefing? Tell us about your experience
Continue reading the latest health & science news with the STAT app
Download on the App Store or get it on Google Play
STAT
STAT, 1 Exchange Place, Boston, MA
©2023, All Rights Reserved.

No comments